Atrial natriuretic peptide counteracts the vasoconstrictor effects of 5-hydroxytryptamine, U46619 and endothelin-1 in the human umbilical artery.
A role for atrial natriuretic peptide (ANP) in maintaining low vascular resistance within the fetoplacental circulation was investigated using isolated strips of human umbilical artery (HUA). Physiological levels of ANP significantly reduced the isometric contractile response of the HUA to U46619 (a stable thromboxane A2 mimetic), to 5-hydroxytryptamine and to endothelin-1, though no effect on agonist sensitivity could be demonstrated. These data suggest that ANP may modify vascular tone in vivo thereby counterbalancing several humoral factors which act to increase vascular resistance within the fetoplacental circulation.
Templeton
A G
AG
Research Division of Syntex Pharmaceuticals Ltd, Edinburgh, Scotland, UK.
Kingdom
J C
JC
Macmillan
J B
JB
McGrath
J C
JC
Whittle
M J
MJ
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D004347:Drug Interactions; D016232:Endothelins / Q000037:antagonists & inhibitors*; D006801:Humans; D011450:Prostaglandin Endoperoxides, Synthetic / Q000037:antagonists & inhibitors*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D014469:Umbilical Arteries / Q000187:drug effects* / Q000502:physiology; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D016232:Endothelins; D011450:Prostaglandin Endoperoxides, Synthetic; D012702:Serotonin Antagonists; D014662:Vasoconstrictor Agents; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D009320:Atrial Natriuretic Factor